Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760

Watchlist Manager
Shenzhen Mindray Bio-Medical Electronics Co Ltd Logo
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Watchlist
Price: 256.55 CNY 0.62% Market Closed
Market Cap: 311.1B CNY
Have any thoughts about
Shenzhen Mindray Bio-Medical Electronics Co Ltd?
Write Note

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Other Current Liabilities
ÂĄ5B
CAGR 3-Years
8%
CAGR 5-Years
20%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Other Current Liabilities
ÂĄ331.4m
CAGR 3-Years
105%
CAGR 5-Years
109%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Other Current Liabilities
ÂĄ587.7m
CAGR 3-Years
-10%
CAGR 5-Years
8%
CAGR 10-Years
26%
J
Jafron Biomedical Co Ltd
SZSE:300529
Other Current Liabilities
ÂĄ318.2m
CAGR 3-Years
17%
CAGR 5-Years
13%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Other Current Liabilities
ÂĄ514.6m
CAGR 3-Years
-12%
CAGR 5-Years
-15%
CAGR 10-Years
14%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Glance View

Market Cap
311.1B CNY
Industry
Health Care

In the bustling city of Shenzhen, China, a thriving enterprise known as Shenzhen Mindray Bio-Medical Electronics Co., Ltd, has cemented its place within the global medical devices market. Born in 1991 amid the backdrop of China’s rapid economic expansion, Mindray embarked on an ambitious journey to revolutionize healthcare technology. The company operates across three main segments: patient monitoring and life support, in-vitro diagnostics, and medical imaging systems. Each category is crucial to the medical infrastructure, with patient monitoring systems tracking vital statistics in real-time, in-vitro diagnostics facilitating intricate lab testing, and medical imaging enabling precise internal examinations. The synergy among these segments allows Mindray to deliver comprehensive solutions that enhance both the quality and efficiency of healthcare systems worldwide. Mindray's business model is intrinsically tied to innovation and global distribution. The company continually invests in research and development, a strategic move that keeps it at the forefront of medical technology advancement. Its R&D centers — strategically located in China, the U.S., and Europe — work tirelessly to push the boundaries of medical technology and address the evolving needs of healthcare professionals. In tandem with its technological prowess, Mindray crafts a robust network of distribution that ensures its advanced devices reach hospitals and clinics across over 190 countries. This expansive market presence, coupled with competitive pricing strategies, has propelled the company to secure a formidable foothold in both emerging and developed economies, thereby transforming the accessibility and delivery of healthcare services on a global scale.

Intrinsic Value
372.4 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's Other Current Liabilities?
Other Current Liabilities
5B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Mindray Bio-Medical Electronics Co Ltd's Other Current Liabilities amounts to 5B CNY.

What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
20%

Over the last year, the Other Current Liabilities growth was 4%. The average annual Other Current Liabilities growth rates for Shenzhen Mindray Bio-Medical Electronics Co Ltd have been 8% over the past three years , 20% over the past five years .

Back to Top